Arcutis Biotherapeutics, Inc. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Arcutis Biotherapeutics, Inc. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Arcutis Biotherapeutics, Inc. do? Business model and key facts
Get the full picture of Arcutis Biotherapeutics, Inc.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 342
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Stocks related to Arcutis Biotherapeutics, Inc.
Selected based on industry alignment and relative market positioning.
Events and news impacting Arcutis Biotherapeutics, Inc. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Arcutis Biotherapeutics, Inc. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
